Latest Insider Transactions at Nurix Therapeutics, Inc. (NRIX)
This section provides a real-time view of insider transactions for Nurix Therapeutics, Inc. (NRIX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Nurix Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Nurix Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 01
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
400
-2.82%
|
$10,400
$26.76 P/Share
|
|
Jul 01
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+2.74%
|
$2,800
$7.26 P/Share
|
|
Jun 10
2021
|
Pierre Beaurang Chief Business Officer |
SELL
Open market or private sale
|
Direct |
7,500
-26.01%
|
$225,000
$30.02 P/Share
|
|
Jun 10
2021
|
Pierre Beaurang Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+38.8%
|
$7,500
$1.11 P/Share
|
|
Jun 10
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,200
-34.89%
|
$34,800
$29.85 P/Share
|
|
Jun 10
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200
+37.44%
|
$1,200
$1.86 P/Share
|
|
Jun 01
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
400
-2.82%
|
$10,800
$27.74 P/Share
|
|
Jun 01
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+2.74%
|
$2,800
$7.26 P/Share
|
|
May 10
2021
|
Pierre Beaurang Chief Business Officer |
SELL
Open market or private sale
|
Direct |
7,500
-27.82%
|
$195,000
$26.87 P/Share
|
|
May 10
2021
|
Pierre Beaurang Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+38.8%
|
$7,500
$1.11 P/Share
|
|
May 10
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,200
-59.85%
|
$32,400
$27.0 P/Share
|
|
May 10
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200
+37.44%
|
$1,200
$1.86 P/Share
|
|
May 06
2021
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,085,784
-24.08%
|
-
|
|
May 05
2021
|
Column Group L P > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
1,619,652
+38.64%
|
-
|
|
May 05
2021
|
Column Group L P > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
2,976,054
-83.43%
|
-
|
|
May 05
2021
|
Column Group L P > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
4,000,000
-58.92%
|
-
|
|
May 03
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
800
-5.48%
|
$27,200
$34.99 P/Share
|
|
May 03
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
800
+5.19%
|
$5,600
$7.26 P/Share
|
|
Apr 28
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
800
-49.84%
|
$28,000
$35.25 P/Share
|
|
Apr 28
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
800
+33.26%
|
$800
$1.86 P/Share
|
|
Apr 12
2021
|
Pierre Beaurang Chief Business Officer |
SELL
Open market or private sale
|
Direct |
7,500
-27.59%
|
$202,500
$27.72 P/Share
|
|
Apr 12
2021
|
Pierre Beaurang Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+28.2%
|
$0
$0.98 P/Share
|
|
Apr 12
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,200
-59.85%
|
$32,400
$27.2 P/Share
|
|
Apr 12
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200
+37.44%
|
$1,200
$1.86 P/Share
|
|
Apr 05
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
400
-2.82%
|
$14,000
$35.0 P/Share
|
|
Apr 05
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+2.74%
|
$2,800
$7.26 P/Share
|
|
Apr 01
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
400
-2.82%
|
$12,400
$31.55 P/Share
|
|
Apr 01
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+2.74%
|
$2,800
$7.26 P/Share
|
|
Mar 25
2021
|
Pierre Beaurang Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,330
+50.0%
|
$0
$0.84 P/Share
|
|
Mar 16
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
800
-5.48%
|
$36,000
$45.0 P/Share
|
|
Mar 16
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
800
+5.19%
|
$5,600
$7.26 P/Share
|
|
Mar 10
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,000
-26.5%
|
$82,000
$41.84 P/Share
|
|
Mar 10
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+41.62%
|
$2,000
$1.86 P/Share
|
|
Mar 08
2021
|
Pierre Beaurang Chief Business Officer |
SELL
Open market or private sale
|
Direct |
7,500
-77.73%
|
$277,500
$37.38 P/Share
|
|
Mar 08
2021
|
Pierre Beaurang Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+50.0%
|
$0
$0.84 P/Share
|
|
Mar 01
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
800
-5.48%
|
$28,000
$35.95 P/Share
|
|
Mar 01
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
800
+5.19%
|
$5,600
$7.26 P/Share
|
|
Feb 24
2021
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
35,419
-100.0%
|
$1,381,341
$39.9 P/Share
|
|
Feb 24
2021
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
35,419
+27.71%
|
$106,257
$3.44 P/Share
|
|
Feb 22
2021
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,330
-100.0%
|
$207,870
$39.93 P/Share
|
|
Feb 22
2021
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,330
+46.17%
|
$5,330
$1.02 P/Share
|
|
Feb 18
2021
|
Pierre Beaurang Chief Business Officer |
SELL
Open market or private sale
|
Direct |
15,000
-61.6%
|
$540,000
$36.0 P/Share
|
|
Feb 18
2021
|
Pierre Beaurang Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+28.33%
|
$75,000
$5.89 P/Share
|
|
Feb 18
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
800
-3.16%
|
$28,800
$36.74 P/Share
|
|
Feb 18
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
800
+5.88%
|
$5,600
$7.26 P/Share
|
|
Feb 18
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,000
-62.92%
|
$70,000
$35.79 P/Share
|
|
Feb 18
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
$2,000
$1.86 P/Share
|
|
Feb 18
2021
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
13,583
-60.97%
|
$488,988
$36.06 P/Share
|
|
Feb 18
2021
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,583
+50.0%
|
$0
$0.84 P/Share
|
|
Feb 04
2021
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
914,216
-16.86%
|
-
|